Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX-009 · 2 trials · 7 indications
Percentage of patients whose Best Overall Response (BOR) is assessed as Complete Response (CR) or Partial Response (PR) as assessed by RECIST 1.1
Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: \>=30% decrease in the sum of the longest diameter of target lesions.
| Arm | Type | Description |
|---|---|---|
| CTX-009 plus Paclitaxel | EXPERIMENTAL | - |
| Paclitaxel | ACTIVE_COMPARATOR | Patients randomized to receive paclitaxel only have the option to crossover to the CTX-009 plus paclitaxel arm after documented disease progression per RECIST v1.1. |
| CTX-009 Treatment | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CTX-009 | DRUG | IV infusion on day 1 and 14 of every 28 day cycle |
| Paclitaxel | DRUG | IV infusion on day 1, 8, and 15 of every 28 day cycle |
INCLUSION CRITERIA 1. 18 years of age or older 2. Histologically or cytologically confirmed unresectable advanced, metastatic, or recurrent biliary tract cancers (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma) 3. Patients mus...
CTX-009 is an investigational small molecule being studied for the treatment of biliary tract cancer and metastatic colorectal cancer. It is currently in Phase 2 clinical development for these oncology indications.
CTX-009 targets DLL4 and VEGF-A, two proteins involved in tumor angiogenesis. By inhibiting these targets, the drug aims to disrupt the blood supply that tumors need to grow and spread.
CTX-009 is being developed by Compass Therapeutics, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol CMPX.
CTX-009 is in Phase 2 clinical development. It has received Fast Track designation from the FDA for its investigation in biliary tract cancer.
CTX-009 is being studied in two Phase 2 trials. NCT05506943 evaluates CTX-009 in combination with paclitaxel in patients with unresectable advanced, metastatic, or recurrent biliary tract cancers. NCT05513742 evaluates CTX-009 in patients with metastatic colorectal cancer.
CTX-009 is not known by any other names in the available information. It is a distinct investigational compound being developed by Compass Therapeutics.